EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers

Jordi Pfeifer Serrahima, Congcong Zhang, Pranav Oberoi, Malena Bodden, Jasmin Röder, Claudia Arndt, Anja Feldmann, Anne Kiefer, Maren Prüfer, Ines Kühnel, Torsten Tonn, Michael Bachmann und 1 weitere

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03374-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Jordi Pfeifer Serrahima und 12 weiteren Autor:innen. Beteiligte Einrichtung: Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Consortium (DKTK), Deutsche Forschungsgemeinschaft (DFG), LOEWE Center Frankfurt Cancer Institute (FCI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-engineered immune effector cells constitute a promising approach for adoptive cancer immunotherapy. Nevertheless, on-target/off-tumor toxicity and immune escape due to antigen loss represent considerable challenges. These may be overcome by adaptor CARs that are selectively triggered by bispecific molecules that crosslink the CAR with a tumor-associated surface antigen. Here, we generated NK cells carrying a first- or second-generation universal CAR (UniCAR) and redirected them to tumor cells with so-called target modules (TMs) which harbor an ErbB2 (HER2)-specific antibody domain for target cell binding and the E5B9 peptide recognized by the UniCAR. To investigate differential effects of the protein design on activity, we developed homodimeric TMs with one, two or three E5B9 peptides per monomer, and binding domains either directly linked or separated by an IgG4 Fc domain. The adaptor molecules were expressed as secreted proteins in Expi293F cells, purified from culture supernatants and their bispecific binding to UniCAR and ErbB2 was confirmed by flow cytometry. In cell killing experiments, all tested TMs redirected NK cell cytotoxicity selectively to ErbB2-positive tumor cells. Nevertheless, we found considerable differences in the extent of specific cell killing depending on TM design and CAR composition, with adaptor proteins carrying two or three E5B9 epitopes being more effective when combined with NK cells expressing the first-generation UniCAR, while the second-generation UniCAR was more active in the presence of TMs with one E5B9 sequence. These results may have important implications for the further development of optimized UniCAR and target module combinations for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansKiller Cells, NaturalImmunotherapy, AdoptiveAntigens, NeoplasmCell Line, TumorErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

Chimeric antigen receptorErbB2HER2NK-92Natural killer cellsUniCAR

Substanzen

Receptors, Chimeric AntigenAntigens, NeoplasmErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany.
  • Partner Site Frankfurt/Mainz, German Cancer Consortium (DKTK), Frankfurt, Germany.
  • German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Frankfurt Cancer Institute, Goethe University, Frankfurt, Germany.
  • Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.

Förderung

  • German Cancer Consortium (DKTK)
  • Deutsche Forschungsgemeinschaft (DFG)
  • LOEWE Center Frankfurt Cancer Institute (FCI)
  • Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus

Zitieren

APA

Pfeifer Serrahima, J., Zhang, C., Oberoi, P., Bodden, M., Röder, J., Arndt, C., Feldmann, A., Kiefer, A., Prüfer, M., Kühnel, I., Tonn, T., Bachmann, M., & Wels, W. S. (2023). Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03374-x

Vancouver

Pfeifer Serrahima J, Zhang C, Oberoi P, Bodden M, Röder J, Arndt C, et al. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03374-x

BibTeX
@article{PfeiferSerrahima2023,
  author = {Pfeifer Serrahima, Jordi and Zhang, Congcong and Oberoi, Pranav and Bodden, Malena and Röder, Jasmin and Arndt, Claudia and Feldmann, Anja and Kiefer, Anne and Prüfer, Maren and Kühnel, Ines and Tonn, Torsten and Bachmann, Michael and Wels, Winfried S},
  title = {Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03374-x}
}
Kostenlos starten →